HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo's Recall Flushes Ranitidine OTC Private Label And Store Brand Products From US Market

Executive Summary

Also added to FDA recalls database are multiple variations of GSK's Advil line found not to include required safety warning information; a California contract manufacturer's 12 protein products due to an unapproved herbicide; and cosmetics firm Tween Brands' third recall in nine months due to an unapproved colorant.

You may also be interested in...



Sanitizers Drive 2020 US OTC Drug Recalls To Double 2019 Total

Sedgwick reported US OTC drug recalls in 2020 doubled to 61 driven by methanol contamination and GMP deviations in hand sanitizers. Once FDA resumes full inspection schedule, enforcement will be “more frequent, penalties will be harsher and cross-agency collaboration” will be welcome.

After NDA Investment For OTC Switch, Success Swings On More Spending For Advertising

Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.

Spike In Drug Recalls Expected As US FDA Resumes Inspections, Targeting COVID-19-Related Problems

Attorneys and recall consultants say any firm distributing products associated with COVID-19 should expect to receive the highest level of scrutiny as the US FDA resumes inspections and uses its enforcement muscle to prohibit companies from making adulterated products, such as hand sanitizers, or making fraudulent claims.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel